Open an account

Enanta Pharmaceuticals

ENTA · NASDAQ

$11.67+$0.26 (+2.28%)TodayMarket closed ·
Prev close $11.41

ENTA analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 8 analysts

Average $22.85 (+95.8% upside)

Low
$20.20
Now
$11.67
High
$33.60

Upgrades and downgrades

The latest rating actions, newest first

ENTA analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 23, 2026MaintainsBuy
HC Wainwright & Co.Jun 23, 2026MaintainsBuy
HC Wainwright & Co.Feb 10, 2026MaintainsBuy
HC Wainwright & Co.Jan 9, 2026MaintainsBuy
JP MorganNov 14, 2025InitiatesOverweight

The case for and against

Updated Oct 9, 2026

Bull case

Enanta Pharma is well positioned by two de-risked value drivers: zelicapavir in RSV and EDP-978 in chronic spontaneous urticaria, both supported by encouraging regulatory and mechanistic data. FDA alignment on a single Phase 2b/3 RSV study in high-risk adults reduces development burden and uncertainty, while management cites ~1.2M annual U.S. adult HR3 patients and 1.5M pediatric at-risk patients, implying a $2B to $2.5B annual opportunity for the currently targeted populations. EDP-978 also has compelling KIT selectivity (>900-fold vs PDGFRα, >800-fold vs PDGFRβ, >30,000-fold vs FLT3), and the upcoming 4Q26 Phase 1 readout could validate target engagement and a clean safety profile, reinforcing the bullish fundamental case.

Bear case

Enanta Pharma is viewed negatively because its valuation depends heavily on a DCF framework that uses a relatively high 13.7% WACC and a 9.5x exit multiple on 2034 estimates, which underscores meaningful uncertainty in long-duration pipeline economics. The outlook is further restrained by assigning only a 50% probability of success to Zelicapavir in RSV and by taking a conservative approach to the rest of the pipeline, limiting confidence in near-term value creation. The thesis is also exposed to multiple risks—clinical development, regulatory, commercial, and intellectual property—and a late 2029 or early 2030 launch assumption suggests cash flow realization remains distant.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.